Stocksigma LogoStocksigma Logo

Anthem Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

■ Revenue: 5,940 (+7.9% YoY | +42.0% QoQ) ■ EBITDA: 2,715 (+24.3% YoY | +80.3% QoQ) ■ EBITDA Margin (%): 45.7 (+603 bps YoY | +970 bps QoQ) ■ PAT: 2,115

Anthem Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million)

Anthem Biosciences Ltd · Outcome · 03 Nov 2026, 11:23 pm

Anthem Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) ■ Revenue: 5,940 (+7.9% YoY | +42.0% QoQ) ■ EBITDA: 2,715 (+24.3% YoY | +80.3% QoQ) ■ EBITDA Margin (%): 45.7 (+603 bps YoY | +970 bps QoQ) ■ PAT: 2,115 (+21.9% YoY | +76.3% QoQ) ■ EPS (INR): 3.72 (+21.6% YoY | +76.3% QoQ) Anthem Biosciences Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Million) Segmental Performance CRDMO ■ Revenue: 5,093 (+9.2% YoY | +49.4% QoQ) ■ EBIT: 3,663 (+28.1% YoY | +57.7% QoQ) ■ EBIT Margin (%): 71.9 (+1061 bps YoY | +377 bps QoQ) Speciality Ingredients ■ Revenue: 848 (+0.6% YoY | +9.5% QoQ) ■ EBIT: 431 (+4.4% YoY | +8.4% QoQ) ■ EBIT Margin (%): 50.8 (+185 bps YoY | -53 bps QoQ)

Original exchange filing (PDF)

More announcements from Anthem Biosciences Ltd

All Anthem Biosciences Ltd announcements